![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Details:
The proceeds will be used to advance the clinical development of Locate Bio's lead product, LDGraft (rhBMP-2), which is currently undergoing evaluation in early-stage clinical trials for treating patients with degenerative disc disease.
Lead Product(s): rhBMP-2
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: LDGraft
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Mercia Ventures
Deal Size: $9.8 million Upfront Cash: Undisclosed
Deal Type: Funding April 29, 2024